BioMedNewsBreaks

MondayNov 15, 2021 12:32 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Uniquely Positioned in Cancer Screening, Detection Market

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is the company behind a proprietary novel technology for early cancer screening and detection — the Cancer Differentiation Analysis (“CDA”). Powered by a database containing over 200,000 samples and cases, AnPac Bio’s CDA technology can detect and carry multifaceted information, including cellular and protein-level details, to determine the existence of cancerous environments. At present, the company’s CDA platform “can detect up to 26 different types of cancer, which gives AnPac Bio a major advantage over industry peers in terms of cost effectiveness, multi-cancer testing, ability…

Continue Reading

FridayNov 12, 2021 3:08 pm

BioMedNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a leader in advanced proprietary technology and research for psychedelics, recently signed a non-binding letter of intent (“LOI”) with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF), a biotech company with clinical operations researching, developing and delivering psychedelic medicine to treat addiction. “Under the LOI, MINDCURE becomes a distributor of Awakn’s ketamine-assisted psychotherapy for alcohol use disorder in the United States and Canada, through its proprietary digital therapeutics platform, iSTRYM,” reads a recent article. In addition to distributing its partners’ protocols, MINDCURE will also be distributing its own protocols through iSTRYM.…

Continue Reading

ThursdayNov 11, 2021 12:46 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Partnerships to Facilitate TRP-8803’s Advancement

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently announced a collaboration with researchers at the University of Wisconsin-Madison as part of preparations toward planned phase 2b studies. Under the partnership, Dr. Paul Hutson, PharmD, and Dr. Christopher Nicholas, Ph.D., will support clinical pharmacology studies for TRP-8803, Tryp’s proprietary drug formulation with a novel route of administration. Once completed, the studies will provide additional regulatory support for TRP-8803. The pair will also serve as investigators on a clinical pharmacology study to evaluate the safety and pharmacokinetics of TRP-8803. “This partnership is the latest in a series of collaborations with scholars, institutions and…

Continue Reading

WednesdayNov 10, 2021 12:46 pm

BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) CMO to Participate in Horizons’ Veterans & Families Forum

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, has announced that chief medical officer Dr. Rakesh Jetly will be part of the Horizons' Veterans & Families Forum. The forum is scheduled for Nov. 10, and Jetly will be a panel member for a presentation titled “The State of Care and the Case for Psychedelic Therapy.” The panel will begin at 7:30 p.m. The event is designed specifically for veterans and will be held in NYC at the Judson Memorial Church; a virtual webcast will…

Continue Reading

WednesdayNov 10, 2021 11:26 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Results, Business Updates for Q1 2022

InMed Pharmaceuticals (NASDAQ: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, has reported its financial numbers and corporate update for first-quarter 2022, the period ended Sept. 30, 2021. Highlights of the report included the company’s completion of the BayMedica acquisition, positioning InMed as an industry leader in the manufacturing and commercialization of rare cannabinoids. In addition, InMed is focused on the process optimization of IntegraSyn(TM) as a solution for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP") rare cannabinoid production. The company is also continuing the preclinical studies of its exclusive glaucoma program, INM-088, in preparation for human…

Continue Reading

TuesdayNov 09, 2021 2:11 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Extending Proprietary Technology, Programs Beyond Traditional Diabetes Market

Nemaura Medical (NASDAQ: NMRD), a cutting-edge medical technology company, recently conducted the beta launch of MiBoKo, a new proprietary metabolic health program designed to utilize a non-invasive glucose sensor and an AI-based mobile application. The MiBoKo application is designed to measure and monitor the user’s metabolic health scores based on glucose tolerance and insulin resistance. The cutting-edge program provides users with personalized information by tracking their metabolism when the app and sensor are used in conjunction with one another. In addition to receiving real-time updates on their metabolic health scores, MiBoKo users will be eligible to receive weekly and monthly…

Continue Reading

TuesdayNov 09, 2021 10:39 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Release Q2 2021 Financial Results, Host Call

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), is planning to release its Q2 2021 financial report on Nov. 15, 2021. The report will cover the period ended Sept. 30, 2021. The company  is also planning on hosting a conference call and webcast the same day, which is scheduled to begin at 4:30 p.m. EST. The call will be hosted by Cybin CEO Doug Drysdale and will provide an overview of the financial results along with relevant business updates. In addition, Drysdale and other team members will answer questions during the call. Those who…

Continue Reading

MondayNov 08, 2021 12:21 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) to Participate in Q4 Virtual Investor Summit

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced its participation in the Q4 Virtual Investor Summit, slated for Nov. 16–17, 2021. According to the announcement, AnPac head of investor relations, Phil Case, will present at the two-day event; AnPac’s presentation will begin at 3:30 p.m. ET on Nov. 17. Case will provide an overview of the company, including a look at how Anpac Bio is democratizing early cancer screening and detection; he will also be available for one-on-one meetings with qualified investors. The company…

Continue Reading

MondayNov 08, 2021 11:00 am

BioMedNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Demonstrates Numerous Advantages over Oral Psilocybin for Treatment of Mental Health

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced positive CYB003 pre-clinical findings. According to the update, the findings demonstrate multiple advantages for Cybin’s newly developed novel deuterated psilocybin analog over oral psilocybin for the treatment of mental health. “Multiple academic studies have shown that psilocybin may have the potential to revolutionize mental health care, but few companies have addressed the well-known limitations and side effects of oral psilocybin,” said Cybin’s CEO Doug Drysdale in the news release. “Cybin has always strived to develop safer and more effective therapies for patients, which…

Continue Reading

ThursdayNov 04, 2021 10:46 am

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Participate in Panel Discussion at Wonderland: Miami

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will participate in Wonderland: Miami, presented by Microdose. The event is set to take place Nov. 8-9, 2021, in Miami, Florida. Tryp’s chairman and CEO Greg McKee will participate in a panel discussion entitled, “Developing Psychedelic Medicine Beyond What We Already Know,” beginning at 2:40 p.m. ET on Nov. 8. In the discussion, McKee will highlight Tryp's leading-edge work with synthetic psilocybin for chronic pain and other indications. To view the full press release, visit https://ibn.fm/S87TX…

Continue Reading